Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies

Struttura Complessa di Cardiologia, Ospedali Galliera, Genoa, Italy. giorgio.egildo.derchi@galliera.it

BACKGROUND AND OBJECTIVES: During the last decade new approaches to the treatment of pulmonary arterial hypertension (PH) have increased symptomatic relief and prolonged survival. PH is a common sequel of the hemoglobinopathies, thalassemia and sickle cell anemia, but the use of standard oral treatment options, such as calcium channel blockers, endothelin receptor antagonists, and long-term anticoagulation therapy, is limited because of toxicity and poor effectiveness. Sildenafil citrate is a selective and potent inhibitor of cGMP-specific phosphodiesterase-5 (PDE5) which promotes selective smooth muscle relaxation in lung vasculature and has been utilized successfully in the treatment of PH. The primary objective of this study was to evaluate the efficacy of sildenafil treatment in the control of PH in patients with hemoglobinopathies. DESIGN AND METHODS: In this study patients with hemoglobinopathies (thalassemia intermedia n=4; thalassemia major n=2; sickle thalassemia n=1) suffering from severe PH were treated with sildenafil citrate (50 mg b.i.d.) for periods ranging from 4 to 48 months. RESULTS: A significant decrease in pulmonary pressure and improvement in exercise capacity and functional class were observed in all patients. No significant adverse events were reported. INTERPRETATION AND CONCLUSIONS: These data, in a small group of patients, indicate that sildenafil citrate is effective in the treatment of PH in hemoglobinopathies that cannot be treated with alternative oral drugs and is well tolerated long-term at a daily dose of 100 mg, though studies including more patients may uncover toxicities and limitations of efficacy.

This article has been cited by other articles:

				G. J. Kato and M. T. Gladwin Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy JAMA, December 10, 2008; 300(22): 2638 - 2646. [Abstract] [Full Text] [PDF]

				L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF]

				D. C. Rees, M. C. Dick, S. E. Height, S. O'Driscoll, K. R.E. Pohl, D. E. Goss, and C. R. Deane A Simple Index Using Age, Hemoglobin, and Aspartate Transaminase Predicts Increased Intracerebral Blood Velocity as Measured by Transcranial Doppler Scanning in Children With Sickle Cell Anemia Pediatrics, June 1, 2008; 121(6): e1628 - e1632. [Abstract] [Full Text] [PDF]

				C. F. Barnett, P. Y. Hsue, and R. F. Machado Pulmonary Hypertension: An Increasingly Recognized Complication of Hereditary Hemolytic Anemias and HIV Infection JAMA, January 23, 2008; 299(3): 324 - 331. [Abstract] [Full Text] [PDF]

				C. R. Morris Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia Hematology, January 1, 2008; 2008(1): 177 - 185. [Abstract] [Full Text] [PDF]

				G. J. Kato Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I Hematology, January 1, 2008; 2008(1): 186 - 192. [Abstract] [Full Text] [PDF]

				A. Aessopos, M. Kati, and D. Farmakis Heart disease in thalassemia intermedia: a review of the underlying pathophysiology Haematologica, May 1, 2007; 92(5): 658 - 665. [Abstract] [Full Text] [PDF]

				V. G. Nolan, D. F. Wyszynski, L. A. Farrer, and M. H. Steinberg Hemolysis-associated priapism in sickle cell disease Blood, November 1, 2005; 106(9): 3264 - 3267. [Abstract] [Full Text] [PDF]